The 94th China International Medical Equipment Fair (CMEF) recently took place in Beijing. AccuMedical was invited to attend as a representative of innovative pharmaceutical and medical device companies, showcasing a comprehensive portfolio of innovative solutions for hemorrhagic and ischemic stroke.
CMEF is the largest and most specialized medical device industry event in the Asia-Pacific region. Widely regarded as a “barometer of the global healthcare industry,” it attracts leading medical device companies from China and around the world each year. This year’s exhibition brought together nearly 3,000 companies from 21 countries and regions, including the United States, the United Kingdom, Germany and France. It welcomed more than 120,000 visits from attendees across over 150 countries and regions, who came to explore products and conduct procurement.

AccuMedical remains focused on unmet clinical needs and continues to advance technological innovation in the treatment of cerebrovascular diseases, including hemorrhagic and ischemic stroke. The company is committed to providing innovative solutions for physicians and patients worldwide. To date, 10 of the company’s products have been approved by China’s National Medical Products Administration (NMPA), providing comprehensive coverage across hemorrhagic stroke, ischemic stroke, and neurointerventional access devices. Several of the company’s core products have also secured market access in key international markets, including the EU under the MDR, the United States, Vietnam and Indonesia, further extending AccuMedical’s global reach.
During the exhibition, healthcare industry representatives, academic experts and partners from around the world visited AccuMedical’s booth for in-depth discussions on its technologies and future development. They spoke highly of AccuMedical’s independently developed neurointerventional solutions.









For hemorrhagic stroke, the Lattice® series of Flow Diverters incorporates a proprietary Mechanical Balloon Delivery System and MIROR Surface Modification Technology. These technologies are designed to improve procedural safety and efficacy, reduce procedural complexity and help usher in an “autopilot” era of intracranial aneurysm treatment.
For ischemic stroke, AccuMedical presented its 4MATIC thrombectomy solution, which combines the Grism® Stent Retriever, Attractor® Intracranial Aspiration Catheter, Cosine®45 Micro-Intermediate Catheter, and Sine®21 Microcatheter. By bringing together the complementary strengths of these devices, the solution supports a broader range of clinical applications.

AccuMedical is accelerating its international expansion and bringing its independently developed innovations to markets worldwide. The Lattice® Flow Diverter and Grism® Stent Retriever have obtained CE certification under the EU MDR. In Indonesia and Vietnam, market access has been secured for these two products, as well as the Attractor® Aspiration Catheter and Sine® Microcatheters. The Cosine®71 Distal Access Catheter has also received U.S. FDA authorization.AccuMedical has now established a comprehensive portfolio for international markets spanning hemorrhagic stroke, ischemic stroke, and neurointerventional access devices. With a total of 12 international registrations and certifications across markets across the United States, the European Union and Southeast Asia, the company continues to strengthen the foundation for its global growth.
At the 94th CMEF, AccuMedical showcased its independently developed technologies and engaged with industry partners from around the world. Looking ahead, the company will continue to develop neurointerventional solutions in response to clinical needs and expand their reach globally, guided by its commitment to physicians and patients: “Treat, as our own.”